ESR1 and breast cancer: For breast cancer (BRCA TCGA cohort), all demographic characteristics as well as estrogen receptor status (n = 969), progesterone receptor status (n = 966), HER2 expression (n = 847), PAM50 subtype (n = 914), TP53 mutational status (n = 1004), immune subtype (n = 1002), and 3-year progression-free survival (n = 458)34 varied significantly between cohorts, with false discovery rate correction and P < 0.05 (Fig. 2).